These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29035637)

  • 1. Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.
    Binz HK; Bakker TR; Phillips DJ; Cornelius A; Zitt C; Göttler T; Sigrist G; Fiedler U; Ekawardhani S; Dolado I; Saliba JA; Tresch G; Proba K; Stumpp MT
    MAbs; 2017; 9(8):1262-1269. PubMed ID: 29035637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
    Baird RD; Linossi C; Middleton M; Lord S; Harris A; Rodón J; Zitt C; Fiedler U; Dawson KM; Leupin N; Stumpp MT; Harstrick A; Azaro A; Fischer S; Omlin A
    J Clin Oncol; 2021 Jan; 39(2):145-154. PubMed ID: 33301375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Half-life extension using serum albumin-binding DARPin® domains.
    Steiner D; Merz FW; Sonderegger I; Gulotti-Georgieva M; Villemagne D; Phillips DJ; Forrer P; Stumpp MT; Zitt C; Binz HK
    Protein Eng Des Sel; 2017 Sep; 30(9):583-591. PubMed ID: 29088432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MP0250, a VEGF and HGF neutralizing DARPin
    Fiedler U; Ekawardhani S; Cornelius A; Gilboy P; Bakker TR; Dolado I; Stumpp MT; Dawson KM
    Oncotarget; 2017 Nov; 8(58):98371-98383. PubMed ID: 29228696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin
    Rao L; De Veirman K; Giannico D; Saltarella I; Desantis V; Frassanito MA; Solimando AG; Ribatti D; Prete M; Harstrick A; Fiedler U; De Raeve H; Racanelli V; Vanderkerken K; Vacca A
    Oncotarget; 2018 Mar; 9(17):13366-13381. PubMed ID: 29568363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.
    Knop S; Szarejko M; Grząśko N; Bringhen S; Trautmann-Grill K; Jurczyszyn A; Vacca A; Khandanpour C; Gamberi B; Pour L; Iversen KF; Stumpp MT; Suter C; Dawson KM; Zitt C; Legenne P; Stavropoulou V; Fey MF; Leupin N; Goldschmidt H
    EJHaem; 2024 Oct; 5(5):940-950. PubMed ID: 39415900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys.
    Kakkar T; Ma M; Zhuang Y; Patton A; Hu Z; Mounho B
    Pharm Res; 2007 Oct; 24(10):1910-8. PubMed ID: 17520181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Antibodies: The DARPin
    Stumpp MT; Dawson KM; Binz HK
    BioDrugs; 2020 Aug; 34(4):423-433. PubMed ID: 32583318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications.
    Stahl A; Stumpp MT; Schlegel A; Ekawardhani S; Lehrling C; Martin G; Gulotti-Georgieva M; Villemagne D; Forrer P; Agostini HT; Binz HK
    Angiogenesis; 2013 Jan; 16(1):101-11. PubMed ID: 22983424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection, purification, and characterization of a HER2-targeting soluble designed ankyrin repeat protein by E. coli surface display using HER2-positive melanoma cells.
    Chen X; Yu X; Song X; Liu L; Yi Y; Yao W; Gao X
    Prep Biochem Biotechnol; 2018 Feb; 48(2):144-150. PubMed ID: 29313422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical development of a humanized neutralizing antibody targeting HGF.
    Kim H; Hong SH; Kim JY; Kim IC; Park YW; Lee SJ; Song SW; Kim JJ; Park G; Kim TM; Kim YH; Park JB; Chung J; Kim IH
    Exp Mol Med; 2017 Mar; 49(3):e309. PubMed ID: 28336956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
    Lin YS; Nguyen C; Mendoza JL; Escandon E; Fei D; Meng YG; Modi NB
    J Pharmacol Exp Ther; 1999 Jan; 288(1):371-8. PubMed ID: 9862791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension.
    Simon M; Frey R; Zangemeister-Wittke U; Plückthun A
    Bioconjug Chem; 2013 Nov; 24(11):1955-66. PubMed ID: 24168270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of murine anti-human Fab antibodies for use in an immunoassay for generic quantification of human Fab fragments in non-human serum samples including cynomolgus monkey samples.
    Stubenrauch K; Wessels U; Essig U; Kowalewsky F; Vogel R; Heinrich J
    J Pharm Biomed Anal; 2013 Jan; 72():208-15. PubMed ID: 23017233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects.
    Martinsson-Niskanen T; Riisbro R; Larsson L; Winstedt L; Stenberg Y; Pakola S; Stassen JM; Glazer S
    Clin Ther; 2011 Sep; 33(9):1142-9. PubMed ID: 21906811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques.
    Feng Y; Zhao Q; Chen W; Wang Y; Crowder K; Dimitrov DS
    Exp Mol Pathol; 2014 Dec; 97(3):359-67. PubMed ID: 25220345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.
    Burgess TL; Sun J; Meyer S; Tsuruda TS; Sun J; Elliott G; Chen Q; Haniu M; Barron WF; Juan T; Zhang K; Coxon A; Kendall RL
    Mol Cancer Ther; 2010 Feb; 9(2):400-9. PubMed ID: 20124448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
    Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.